← Eichor
Condition: Hodgkin Lymphoma Adult Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hodgkin Lymphoma Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT06563245Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Phase 2 · 2 location(s) · University of Utah · NCT06390956Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 · 3 location(s) · Beth Israel Deaconess Medical Center · NCT06510361Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Phase 1 · 7 location(s) · Marker Therapeutics, Inc. · NCT05798897Remission in Adults With Severe Asthma in Thailand
Phase N/A · 1 location(s) · Thammasat University · NCT07328035Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leu
Phase 3 · 460 location(s) · Alliance for Clinical Trials in Oncology · NCT03150693A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07072169Cognitive Screening Made Easy for PCPs - Administrative Supplement
NA · 3 location(s) · University of Texas at Austin · NCT06928298A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06696833Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Princess Maxima Center for Pediatric Oncology · NCT04925609Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05098613Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignanci
Phase 1 · 1 location(s) · University of Kansas Medical Center · NCT06879340Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT06421987A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · 168 location(s) · Regeneron Pharmaceuticals · NCT06091865Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Epcoritamab and Rituximab for First-line Follicular Lymphoma
Phase 2 · 6 location(s) · Reid Merryman, MD · NCT05783609A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06765317Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Phase 2/Phase 3 · 1 location(s) · Hospital Regional de Alta Especialidad del Bajio · NCT05595447AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · 407 location(s) · National Cancer Institute (NCI) · NCT05675410CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 · 1 location(s) · Northside Hospital, Inc. · NCT05909059BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07009002
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.